Press release from Companies

Published: 2015-03-03 08:47:51

WntResearch AB: WntResearch announces changes to the Board

WntResearch AB today announces that Peter Ström will be proposed for election as a new member of the Company Board of Directors at the Company’s Annual General Meeting (June 9, 2015). Peter Ström, who from now on will attend the Board meetings as an observer, has held various senior international positions in KabiVitrum/KabiPharmacia/ PharmaciaUpjohn and IMS Health for more than 20 years. He has also served as a Board member of ActiveBiotech, Oasmia and P.U.L.S AB. Presently he is on the Board of LIDDS and Stockholm Corporate Finance and some other private companies. Peter Ström is a graduate from The Stockholm School of Economics.

Nils Brünner, CEO says, "With Peter Ström on the Board, the company's work on business development will be greatly enhanced. I look forward to working with Peter, who is very knowledgeable and experienced and whose expertise fits very well into the current and future needs of WntResearch.” For additional information please contact: Nils Brünner, CEO E-mail: Telephone: + 45 2614 4708 About WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.

Läs mer hos Cision
Read more about WntResearch AB